Precigen Inc (PGEN)
Healthcare
Biotechnology
6.50 $
-1.2%
vs. previous close
Closing price · As of: 4. Aug 2026
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
| Tick rows to compare them in a chart (up to 4) | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +73.8% | +70.6% | +202.7% | +141.4% | +10.0% | +21.0% | -30.5% | -80.1% | +0.0% | -55.4% | +88.6% | -76.9% | -36.9% | +146.7% | |
| – | – | -24.8% | -60.0% | +231.9% | -3.6% | +1.9% | +0.8% | -91.5% | +733.7% | +19.8% | -88.2% | -3.5% | -30.3% | +42.9% | |
| – | -725.3% | – | – | +108.2% | +17.9% | +30.1% | -42.2% | -72.6% | -148.1% | – | – | -99.5% | -422.6% | – | |
| – | -8.6% | -25.0% | +22.5% | +150.0% | -24.0% | +27.7% | +182.5% | -90.3% | +0.0% | +21.6% | -1.6% | +3.1% | +9.2% | -24.5% | |
| – | – | +35.0% | +89.3% | +71.3% | +30.5% | +2.7% | -5.7% | -26.8% | -9.1% | -19.2% | -35.2% | -15.8% | +2.2% | +69.8% | |
| – | -1.5% | -8.2% | +49.9% | +109.2% | -0.8% | +13.7% | +87.5% | -79.2% | -34.9% | -28.5% | +83.3% | +3.7% | +34.9% | -18.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -68.9% | +147.4% | +372.3% | +86.8% | -30.8% | -29.0% | +1,296.1% | +113.5% | +1.0% | +1.9% | -63.9% | -93.1% | -98.7% | +64,350.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -274.7% | – | – | – | -481.6% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -438.7% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: August 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.